Why This FDA Approval Is a Game Changer for Eli Lilly
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. Revenue of $28.3 billion last year has steadily grown by 24% from the $22.9 billion the healthcare business reported in 2017. And there's potential for the company to continue to get even bigger.
One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). But it's what the treatment isn't approved for yet that has analysts and investors excited.
Image source: Getty Images.
Source Fool.com
